BioSig’s Cardiac Sign Processing Know-how To Be
Westport, CT, Aug. 17, 2022 (GLOBE NEWSWIRE) — BioSig Applied sciences, Inc. (NASDAQ: BSGM) (“BioSig” or the “Firm”), a medical expertise firm advancing electrophysiology workflow by delivering higher intracardiac sign constancy by its proprietary sign processing platform, at this time introduced its participation within the Kansas Metropolis Coronary heart Rhythm Symposium, being held on August 20-21, 2022. The Firm’s PURE EP ™ System, a non-invasive gadget that goals to drive procedural effectivity and efficacy in cardiac electrophysiology, can be highlighted in a doctor presentation through the symposium.
The presentation, titled, “Going Again to Outdated Faculty – Leveraging EGMs to Enhance Efficacy, Security of Ablation” can be carried out throughout a symposium session starting at 12:30 PM ET on Sunday, August 21, 2022. Hicham El Masry. M.D., a Cardiac Electrophysiologist at Mayo Clinic’s Arizona Campus, will focus on the scientific benefits of the PURE EP™ System and the affect the expertise has made on his electrophysiology (EP) observe and procedural workflow.
Through the occasion, the Firm’s scientific and business groups will host product demonstrations that can showcase the newest developments and software program options of its PURE EP ™ System. The Firm can even present an replace on developments in its scientific pipeline.
“We’re wanting ahead to returning to KCHRS, with the newest developments of the PURE EP™ System which were demonstrated and featured by one in every of our earliest adopters,” commented Grey Fleming, Chief Commercialization Officer, BioSig Applied sciences, Inc. “We wish to thank Dr. Lakkireddy for permitting us to be part of such an necessary assembly and Dr. El Masry for representing our expertise on the symposium.”
To register for the occasion, please click on right here.
BioSig lately introduced the graduation of a physician-initiated analysis protocol that can analyze the indicators acquired by its PURE EP™ System throughout Radiofrequency (RF) ablation. Led by Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas Metropolis Coronary heart Rhythm Institute, the one middle research underway at Overland Park Regional Medical Heart, is formally registered with clinicaltrials.gov [NCT05464537], and consists of 30 individuals with paroxysmal atrial fibrillation (AF) present process pulmonary vein isolation (PVI).
About KCHRS 2022
The Kansas Metropolis Coronary heart Rhythm Symposium is an EP-focused medical training occasion for the neighboring 4 state areas. A wide range of subjects will present specialists and generalists an replace on the evolution of illness processes, diagnostic instruments, therapeutic methods and moral points within the development of affected person care. To be taught extra go to, www.kchrs.com.
About BioSig Applied sciences
BioSig Applied sciences is a medical expertise firm commercializing a proprietary biomedical sign processing platform designed to enhance sign constancy and uncover the total vary of ECG and intra-cardiac indicators (www.biosig.com).
The Firm’s first product, PURE EP™ System, is a novel sign processing and acquisition platform designed to extract superior diagnostic and therapeutic knowledge that enhances doctor workflow and will increase throughput. PURE EP™ was engineered to handle the restrictions of current EP applied sciences by empowering physicians with superior indicators and actionable insights.
The Firm is in a nationwide business launch of the PURE EP™ System. The expertise is in common use in a number of the nation’s main facilities of excellence, together with Mayo Clinic, and Texas Cardiac Arrhythmia Institute at St. David’s Medical Heart.
Medical knowledge acquired by the PURE EP™ System in a multi-center research at facilities of excellence together with Texas Cardiac Arrhythmia Institute at St. David’s Medical Heart was lately printed within the Journal of Cardiovascular Electrophysiology and is accessible electronically with open entry through the Wiley On-line Library. Research outcomes confirmed 93% consensus throughout the blinded reviewers with a 75% total enchancment in intracardiac sign high quality and confidence in decoding PURE EP(T.M.) indicators over typical sources.
This press launch comprises “forward-looking statements.” Such statements could also be preceded by the phrases “intends,” “could,” “will,” “plans,” “expects,” “anticipates,” “tasks,” “predicts,” “estimates,” “goals,” “believes,” “hopes,” “potential” or comparable phrases. Ahead- wanting statements are usually not ensures of future efficiency, are primarily based on sure assumptions and are topic to numerous recognized and unknown dangers and uncertainties, lots of that are past the Firm’s management, and can’t be predicted or quantified and consequently, precise outcomes could differ materially from these expressed or implied by such forward-looking statements. Such dangers and uncertainties embody, with out limitation, dangers and uncertainties related to (i) market situations and the Firm’s meant use of proceeds, (ii) the geographic, social and financial affect of COVID-19 on our means to conduct our enterprise and lift capital sooner or later when wanted, (iii) our incapacity to fabricate our merchandise and product candidates on a business scale on our personal, or in collaboration with third events; (iv) difficulties in acquiring financing on commercially affordable phrases; (v) modifications within the measurement and nature of our competitors; (vi) lack of a number of key executives or scientists; and (vii) difficulties in securing regulatory approval to market our merchandise and product candidates. Extra detailed details about the Firm and the danger elements that will have an effect on the conclusion of forward-looking statements is about forth within the Firm’s filings with the Securities and Alternate Fee (SEC), together with the Firm’s Annual Report on Type 10-Ok and its Quarterly Experiences on Type 10-Q. Buyers and safety holders are urged to learn these paperwork freed from cost on the SEC’s web site at http://www.sec.gov. The Firm assumes no obligation to publicly replace or revise its forward-looking statements because of new data, future occasions or in any other case.